Fas ligand (FasL) is a peptide that plays an important immunoregulatory role in limiting the host immune response. Several studies have shown that the expression of FasL in the anterior chamber of the eye and the testis allows these tissues to be immunoprivileged sites. Immunotolerance is achieved by binding of FasL to its receptor (Fas) on activated immune cells, which results in cell apoptosis. To determine whether FasL has a role in maternal immune tolerance to the fetus, we looked for the expression of FasL in the human placenta. Immunoperoxidase staining localized FasL to both syncytiotrophoblast and cytotrophoblast in placental villi and chorionic extravillous trophoblast. Western analysis demonstrated FasL in placental villi and a human first-trimester trophoblast cell line (ED 27 ). In contrast, Fas was colocalized to CD45 (leukocyte common antigen) positive cells found in maternal decidua. When isolated peripheral blood lymphocytes were induced to express Fas with phytohemagglutinin (PHA) and interleukin-2 (IL-2) and then cocultured with trophoblast, 30% of the lymphocytes underwent apoptosis, as determined by the in situ death (TUNEL) assay. Neutralizing antibodies to FasL inhibited apoptosis by 40% in these studies. In contrast, activated lymphocytes cocultured with non-FasL-expressing fibroblasts or unactivated nonFas-expressing lymphocytes cocultured with ED 27 trophoblast showed little evidence of apoptosis. These findings suggest that FasL expressed by fetal trophoblast cells can induce apoptosis in activated lymphocytes there by providing a mechanism for maternal immune tolerance to the fetus. (J Clin Endocrinol Metab 84: 2188 -2194, 1999) T HE FETUS is a unique individual, whose genetic makeup is equally derived from both the mother and father. The fetus can be considered a semiallograft to the mother's immune system and consequently should generate a maternal immune rejection response (1). In the majority of cases, however, a maternal immune rejection response against the fetus does not occur, and instead, a process of maternal immune tolerance to the fetus takes place. The main site of immune interaction between the fetus and the mother is where the maternal decidua and fetal placenta are in intimate contact and is called the maternal-fetal interface. The placenta and placental membranes actually provide a barrier between the fetus and the maternal immune system so that the majority of maternal immune interaction is with the placenta and not the fetus (2). The predominant cell type of the placenta that comes into contact with the maternal immune system is trophoblast. Consequently, most discussions concerning maternal immune recognition of the fetus are really concerned with maternal immune recognition of placental trophoblast. Abnormalities of maternal immune tolerance to the fetus have been implicated in several disease processes of pregnancy, including recurrent miscarriage (3) and preeclampsia (4). Unfortunately, the basic mechanisms involved in maternal immune tolerance to the fetal semiallograft are poorly understood.
Fas was colocalized to CD45 (leukocyte common antigen) positive cells found in maternal decidua. When isolated peripheral blood lymphocytes were induced to express Fas with phytohemagglutinin (PHA) and interleukin-2 (IL-2) and then cocultured with trophoblast, 30% of the lymphocytes underwent apoptosis, as determined by the in situ death (TUNEL) assay. Neutralizing antibodies to FasL inhibited apoptosis by 40% in these studies. In contrast, activated lymphocytes cocultured with non-FasL-expressing fibroblasts or unactivated nonFas-expressing lymphocytes cocultured with ED 27 trophoblast showed little evidence of apoptosis. These findings suggest that FasL expressed by fetal trophoblast cells can induce apoptosis in activated lymphocytes there by providing a mechanism for maternal immune tolerance to the fetus. (J Clin Endocrinol Metab 84: 2188 -2194, 1999) T HE FETUS is a unique individual, whose genetic makeup is equally derived from both the mother and father. The fetus can be considered a semiallograft to the mother's immune system and consequently should generate a maternal immune rejection response (1) . In the majority of cases, however, a maternal immune rejection response against the fetus does not occur, and instead, a process of maternal immune tolerance to the fetus takes place. The main site of immune interaction between the fetus and the mother is where the maternal decidua and fetal placenta are in intimate contact and is called the maternal-fetal interface. The placenta and placental membranes actually provide a barrier between the fetus and the maternal immune system so that the majority of maternal immune interaction is with the placenta and not the fetus (2) . The predominant cell type of the placenta that comes into contact with the maternal immune system is trophoblast. Consequently, most discussions concerning maternal immune recognition of the fetus are really concerned with maternal immune recognition of placental trophoblast. Abnormalities of maternal immune tolerance to the fetus have been implicated in several disease processes of pregnancy, including recurrent miscarriage (3) and preeclampsia (4) . Unfortunately, the basic mechanisms involved in maternal immune tolerance to the fetal semiallograft are poorly understood.
Fas ligand (FasL) and its receptor, Fas, are known to play an important role in regulation of the immune response. Fas is a type I membrane protein that belongs to the tumor necrosis factor and nerve growth factor receptor family (5). Fas is highly expressed on activated T cells and B cells, NK cells, and macrophages. FasL is a type II membrane protein also related to the tumor necrosis factor family (5) . FasL can either be membrane bound (42-48 kDa form) or can be cleaved by metalloproteinases to release the extracellular portion as soluble FasL (sFasL), which is 26 kDa in size (6) . FasL is expressed by activated T cells, cytotoxic T lymphocytes, sertoli cells of the testis, and corneal epithelium and endothelium (7) (8) (9) . The major function of Fas/FasL interaction and Fas activation is the induction of cell apoptosis (10) .
Recent studies have demonstrated that the immunoprivileged nature of the testis and anterior chamber of the eye is caused by the expression of FasL in these tissues. When T cells are activated by infection or foreign antigens, they express Fas. Activation of T cells in the testis or anterior chamber of the eye results in apoptosis of these cells secondary to the local production of FasL (8, 9) . The immunoprotective effect of FasL has recently been exploited in transplantation biology by transfecting myoblasts with FasL complementary DNA (11) . Cotransplantation of these FasL-expressing myoblasts with pancreatic islet cells into donor mice of a different strain resulted in functional islet cells that were not rejected by the host immune system. These studies demonstrate the importance of Fas/FasL in peripheral localized immunotolerance to foreign antigens. These findings also suggest that Fas/FasL could be a very elegant mechanism for local maternal immunotolerance of the fetal semiallograft during pregnancy.
To test the hypothesis that Fas/FasL interaction is a mechanism in human maternal immunotolerance to the fetus, we first characterized the expression of Fas/FasL in tissues at the maternal-fetal interface. Subsequently, we used human ED 27 trophoblast cells and lymphocytes from newborn cord blood as a model to determine whether FasL-expressing trophoblast cells could induce apoptosis in activated lymphocytes in vitro.
Materials and Methods

Placental tissues and cell lines
The protocol for this study was approved by our institution's Committee for the Conduct of Human Research before obtaining any tissue samples. Term placentas (37-40 weeks gestation) were obtained from patients undergoing uncomplicated repeat cesarean section. Early second-trimester placentas (14 -20 weeks gestation) were obtained from patients undergoing elective surgical pregnancy terminations. A firsttrimester human trophoblast cell line (ED 27 
Immunolocalization of Fas, FasL, and CD45
Immunohistochemical staining for Fas was performed on 10-m frozen sections of placenta (N ϭ 5) post-fixed in acetone at 4 C for 10 min. The primary antibody that was used for Fas detection was a mouse monoclonal antihuman Fas antibody (2 g/mL, PharMingen, Los Angeles, CA). Immunohistochemical staining for FasL was performed on formalin-fixed, paraffin-embedded 5-m sections of placenta using a rabbit IgG anti-FasL antibody (0.5 g/mL; Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Localization of the primary antibody was performed using the Elite kit (Vector Laboratories, Inc., Burlingame, CA) and diaminobenzidine as the color substrate. The sections were then counterstained with hematoxylin. Negative controls included preabsorption of the primary antibody with excess FasL peptide (Santa Cruz Biotechnology, Inc.) or substituting the specific primary antibody with nonspecific antibody of the same isotype and concentration.
Colocalization of Fas and CD45 (leukocyte common antigen) was performed using a modification of the EnVison Doublestain System (DAKO Corp., Carpinteria, CA) on 10-m frozen tissue sections. After blocking the slide for endogenous peroxidase activity and nonspecific binding, 1 g/mL anti-Fas antibody (PharMingen) was incubated with the tissue sections for 1 h and detected using the HRP-labeled antibody polymer and diaminobenzidine as substrate. The tissue sections were then again blocked for nonspecific binding and for endogenous biotin (Vector Laboratories, Inc.), followed by incubation with anti-CD45 antibody (400 ng/mL, Novocastra Laboratories, Newcastle, UK) for 1 h. The CD45 antibody was detected by incubating the slides with biotinylated antimouse antibody (1:200, Vector Laboratories, Inc.), followed by strepavidin-Texas Red (10 g/mL, Molecular Probes, Inc., Eugene, OR). Colocalization of Fas and CD45 was accomplished by photographing the tissue section using fluorescence microscopy (CD45), immediately followed by bright-field photomicroscopy (Fas) of the same microscopic field. Specificity controls consisted of substituting the anti-Fas and/or the anti-CD45 antibodies with nonspecific isotype matched antibodies at the same concentration.
FasL Western blot analysis
To perform Western blot analysis for FasL, intact placental villi, 96-h phytohemagglutinin (PHA)/interleukin (IL)-2 activated lymphocytes, ED 27 trophoblast cells, or WS1 fetal fibroblasts were homogenized in RIPA buffer (5 mmol Tris, 150 mmol NaCl, 1% Nonidet P-40, 0.5% Na deoxycholate, 0.1% SDS, pH 7.5). The homogenate was clarified by centrifugation, and total protein content of the supernate was determined by a Coomassie protein assay using albumin as the standard (Pierce Chemical Co., Rockford IL). For FasL Western analysis, 50 g of total cellular protein was fractionated in a denaturing 10% SDS-polyacrylamide gel by electrophoresis. The fractionated protein samples were then transferred to nitrocellulose membranes (Schleicher & Schuell, Inc., Keene, NH), and nonspecific binding was blocked for 2 h in 5% nonfat dry milk in Tris-buffered saline. The membranes were incubated with 0.3 g/mL of rabbit IgG antibody (Santa Cruz Biotechnology, Inc.) developed against a synthetic FasL peptide that corresponds to the intracellular portion of the FasL molecule, or 0.3 g/mL of nonspecific rabbit IgG antibody as a control. Development of the Western blots was performed using the ECL system (Amersham, Arlington Heights, IL).
Peripheral blood lymphocyte isolation
To obtain peripheral blood lymphocytes, mononuclear cells were isolated from heparinized peripheral blood from newborn infants (placental cord blood, N ϭ 4) by Histopaque-1077 (Sigma Chemical Co., St. Louis, MO) density centrifugation. The mononuclear cell layer was recovered and washed in RPMI 1640 media (Gibco BRL). The cells were then placed in plastic culture flasks in RPMI with 5% FCS at a concentration of 2 ϫ 10 6 for 1 h at 37 C, in 5% CO 2 /air, to allow the monocytes to adhere. The nonadherent lymphocytes were then recovered by gentle rinsing with RPMI 1640, and the adherence procedure was repeated. The nonadherent lymphocytes were then recovered and used for study.
FACS analysis for Fas expression in activated lymphocytes
Isolated lymphocytes were activated by incubation in RPMI 1640 with 10% FCS, 10 g/mL of phytohemagglutinin (Sigma Chemical Co.), and 10 ng/mL of IL-2 (PharMingen) for 24 h at 37 C in 5% CO 2 /air. The lymphocytes were then washed and incubated in RPMI 1640 with 10% FCS and 10 ng/mL of IL-2 for an additional 48 h to induce Fas expression, and for 96 h to induce FasL expression (7) . For FACS analysis of Fas expression, activated or unactivated lymphocytes were incubated with either 10 g/mL of fluorescein isothiocyanate (FITC) labeled antiFas antibody or FITC-labeled isotype-matched nonspecific antibody control (PharMingen) for 1 h at 4 C. The cells were washed and analyzed for Fas expression using a FACScan flow cytometer (Becton Dickson and Co., Franklin Lakes, NJ).
TUNEL (in situ death) assay for trophoblast-induced lymphocyte apoptosis
ED 27 trophoblast cells and WS1 fibroblast cells were grown in 6-well plates in their respective growth media. Once confluent, the media was changed to RPMI 1640 with 10% FCS and either 1 ϫ 10 5 activated or unactivated lymphocytes was added to the wells (N ϭ 3 for each treatment), resulting in a target:effector cell ratio of approximately 1:20. After 24 h of coculture, the wells were gently rinsed to recover the nonadherent lymphocytes. Cytospin cell preparations of the lymphocytes were fixed in 4% formalin at room temperature for 30 min. After fixation, the slides were washed in PBS and treated with acetic acid:ethanol (1:2) at Ϫ20 C for 10 min. The slides were washed in PBS and then blocked with 0.1% BSA for 30 min. The slides were washed once in PBS and then in H 2 O. The TUNEL reaction mixture (Boehringer Mannheim, Indianapolis, IN) was applied to the slides and then incubated at 37 C for 1 h to label 3Ј DNA ends with FITC-labeled deoxyuridine 5Ј-triphosphate. Apoptotic cells were observed under phase and fluorescence microscopy. Three random 200 ϫ microscopic fields per slide were photographed, and the number of positively fluorescing nuclei and the total number of cells were counted. Occasional nonadherent dead trophoblast cells could be readily distinguished morphologically from lymphocytes by their large sized and substantially increased cytoplasmic-to-nuclear ratio. These experiments were performed on lymphocytes isolated from four different individuals, and the results were analyzed by ANOVA for statistical comparisons. To demonstrate the specificity of the FasL-induced apoptosis by trophoblast on activated lymphocytes, 10 g/mL of neutralizing anti-FasL antibody (NOK-2, PharMingen) or nonspecific control antibody was added to trophoblast/activated lymphocyte coculture experiments to inhibit FasL activity.
Results
FasL was found to be localized mainly to both syncytiotrophoblast and cytotrophoblast in fetal placental villi by im-munohistochemistry (Fig. 1A) . In addition, extravillous cytotrophoblast in the chorion of the placental membranes also localized immunoreactive FasL (Fig. 1C) . These are the sites where fetal tissues would be in contact with the maternal immune system. The specificity of the antibody staining was verified by the lack of any specific staining with anti-FasL antibody preabsorbed with FasL peptide (Fig. 1B) or with nonspecific control antibody (data not shown). Fas localization was seldom seen in the fetal placental villi but instead was found in occasional cells of the maternal decidual tissues (Fig. 1D) . The specificity of the Fas antibody staining was verified by the lack of staining with nonspecific control antibody (Fig. 1E) . The colocalization experiments for Fas and CD45 demonstrated that some of the Fas-expressing cells in maternal decidua were leukocytes (Fig. 2, A and B) . These experiments also showed that not all CD45 positive cells in decidua expressed Fas, and not all Fas positive cells expressed CD45. Substitution of the anti-Fas or anti-CD45 antibodies with nonspecific isotype specific antibody at the same concentration resulted in no specific staining (Fig. 2, C  and D) , demonstrating the specificity of the colocalization staining procedure.
To verify our immunohistochemistry results for FasL, Western blot analysis was performed. As seen in Fig. 3 Lymphocytes isolated from newborn peripheral blood were used for studies concerning Fas/FasL-induced apoptosis because these lymphocytes are naïve and do not express Fas antigen (Fig. 4A ). After activation with PHA and IL-2 for 72 h, however, a marked up-regulation of Fas antigen expression was seen (Fig. 4B) but not FasL (results not shown). When activated lymphocytes that express Fas were cocultured with FasL-expressing ED 27 trophoblast for 24 h, 30% of the lymphocytes underwent apoptosis, as determined by the TUNEL assay (Fig. 5B) . In these experiments, lymphocyte apoptosis was caused by ED 27 trophoblast cell FasL activation of Fas expressed on the lymphocytes because apoptosis was inhibited by 40% with the addition of neutralizing antibody to FasL (Fig. 6 ). In addition, coculture of unactivated non-Fas-expressing lymphocytes with ED 27 trophoblast (Fig.   5D ) or activated lymphocytes with non-FasL-expressing WS1 fetal fibroblast cells (Fig. 5F ) resulted in only minimal lymphocyte apoptosis of 4 -5%.
Discussion
This study has demonstrated that human fetal trophoblast cells express FasL. These findings are consistent with a recent study that demonstrated FasL messenger RNA in placental villi and choriocarcinoma cell lines (12) . In contrast to FasL, Fas was mainly localized to cells found in the maternal decidua, some of which are maternal leukocytes. Furthermore, using a model of ED 27 trophoblast cocultured with isolated cord blood lymphocytes, we have demonstrated that FasL expressed on trophoblast cells can induce apoptosis in activated peripheral lymphocytes. Because trophoblast form the fetal interface with the maternal immune system, these findings support our hypothesis that expression of FasL on trophoblast provides a local mechanism for maternal immunotolerance to the fetus.
The need for local immune tolerance mechanisms at the maternal-fetal interface comes from numerous studies suggesting that the maternal immune system initiates an immune response directed against the fetus. During pregnancy, there is a large influx of macrophages and lymphocytes into the decidua at the maternal-fetal interface. Leukocytes comprise up to 40% of the cells found in decidua during pregnancy (13) . Cytokines such as IL-1 and IL-6 are up-regulated in decidua during pregnancy, along with human leukocyte antigen (HLA)-DR (14, 15) . Findings of increased leukocytic infiltrates and elevated IL-1 and HLA-DR expression are also found during transplant organ graft rejection (16) . Finally, some mothers are known to develop antibodies directed against paternal HLA antigens found in the fetus (16a), in addition to antibodies directed against the placenta (17) . These findings are consistent with a maternal immune response directed toward the fetus.
Given the many different effector arms of the immune system, it is not surprising that a number of mechanisms, other than Fas/FasL, have been described for maternal immune tolerance to the fetus. Central to all of these mechanisms is the fact that maternal immunotolerance during pregnancy is a phenomena mainly localized to the maternalfetal interface. A primary mechanism for maternal immune tolerance to the fetus is the lack of classic major histocompatibility complex (MHC) antigen expression on trophoblast cells (18) . Trophoblast do express a unique major histocompatibility complex (MHC) class I antigen designated HLA-G, but this antigen has very limited polymorphism, does not seem to stimulate T cell activation (19) , and inhibits NK cell activity (20) . A number of immunosuppressive substances are at the maternal-fetal interface. One of the most potent of these immunosuppressive substances is transforming growth factor-␤ (TGF-␤). TGF-␤ is a multifunctional peptide with potent immunosuppressive activities, including inhibition of IL-1-induced lymphocyte proliferation, lymphokine-activated killer cell activity, cytotoxic T cell activity, natural killer cell activity, and macrophage cytotoxicity (21) (22) (23) (24) . Both the placenta and placental membranes produce significant amounts of bioactive TGF-␤ throughout pregnancy (15) . Other substances produced by the placenta that can suppress cell-mediated immunity are PGE 2 , prostacyclin, and progesterone (25) (26) (27) . Protection from maternal humoral immunity comes from several mechanisms. The rapid binding and internalization of antibody by Fc receptors on the trophoblast helps remove maternal antibodies which might result in complement fixation or help mediate antibodydependent cell-mediated cytotoxicity (28) . In addition, trophoblast cells express CD59, which is an inhibitor of the complement cascade (29) . Taken together, these findings suggest there are multiple mechanisms to prevent maternal immune rejection of the fetus.
Although Fas/FasL probably plays an active role in maternal immunotolerance to the fetus, the absolute necessity of trophoblast FasL expression for maternal immunotolerance of the fetus has not been demonstrated. Mice with nonfunctional mutations of FasL (gld) can reproduce. These mice, however, lack functional FasL, which is expressed on normal mouse trophoblast and is thought to prevent trafficking of maternal activated lymphocytes to the placenta (30) . Consequently, gld mice tend to have smaller litters and more fetal resorptions which are associated with placental inflammatory infiltrates. In the absence of a functional Fas/FasL system, other mechanisms for maternal immunotolerance to the fetus are sufficient to prevent absolute pregnancy failure but insufficient to prevent reduced reproductive efficiency. Another function of trophoblast FasL expression could be to reduce the inflammatory response to vaginal bacteria that gain access to the placental membranes through a partially dilated cervix. Both neutrophils and monocytes constitutively express Fas and undergo apoptosis in the presence of FasL (31) . Limiting the inflammatory response to bacteria would be beneficial because chorioamnionitis is associated with increased local production of PGs, which can result in uterine contractions and premature labor and delivery.
In conclusion, our findings, demonstrating the expression of FasL on trophoblast at the maternal-fetal interface and the ability of FasL-expressing trophoblast cells to induce apoptosis in activated lymphocytes, may help to identify a mechanism for maternal immunotolerance to the fetus in human pregnancy.
FIG. 6.
Comparison of apoptosis in cocultured lymphocytes. To determine the number of lymphocytes that underwent apoptosis in the coculture experiments, photomicrographs were taken under phase contrast (total cells) and corresponding fluorescence views (apoptotic cells), and the cells were counted. The percent of apoptotic cells was then determined. The data represent the mean and SEM of four separate experiments. Both control groups, including activated lymphocytes cocultured on WS1 fibroblasts (A) and unactivated lymphocytes cocultured on ED 27 trophoblast (B), showed only low levels (6%) of lymphocyte apoptosis. In contrast, activated lymphocytes cocultured on ED 27 trophoblast (C) had significantly higher levels of apoptosis, compared with the controls (30%, P Ͻ 0.01, -square analysis). The addition of FasL neutralizing antibody (D) at the beginning of the coculture experiments with activated lymphocytes and ED 27 trophoblast resulted in a 40% decrease in lymphocyte apoptosis, compared with the coculture experiments without the FasL neutralizing antibody (P Ͻ 0.05, -square analysis).
